On Jan. 04, Mandelia Ashish divested U.S. $6,610 in shares of Mersana Therapeutics Inc.. The VP, Controller sold 247 shares at a price per share of $26.76. The transaction decreased this specific insider’s holdings to 0 shares worth around $0.0 at present.
Stifel launched its Mersana Therapeutics Inc. [MRSN] rating to the equivalent of a Buy and assigned the price target of $33, in a research note dated December 03, 2020. That figure represents around a 44.88% premium from where the company’s shares closed on Wednesday. Some new analysts also started their coverage, with Stifel’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in early December. In addition, there was a new coverage from BTIG Research on April 29, 2020. The research firm rated MRSN “a Buy”.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Is Mersana Therapeutics Inc. [NASDAQ:MRSN] a Good Buy Right Now?
It should be noted that MRSN technical indicators for short, intermediate as well as long term progress have placed an overall average of 8% as Buy. The average signal changed from 100% Buy in the last week and compares with 88% Buy in the past month. Data from Mersana Therapeutics Inc.’s Trend Spotter indicated that the signals were Weakest. The stock current average is 1.53 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 1.11 million shares while the medium term average advocated for 50% Buy. The average long-term signal stands at 50% Sell and the 100-day average volume stands at 1.05 million shares.
MRSN Price Performance
On Wall Street, Mersana Therapeutics Inc. [NASDAQ:MRSN] finished Wednesday’s session down -2.73% at $18.19. The stock went up to $19.28 at the same session while its lowest single day price was $17.83. In the last five days, it saw a fall of about -32.83%, Mersana Therapeutics Inc. shares dropped by almost -31.64% since the beginning of the year. However, the share price has dropped to as low as -37.47% below its one year high. On 01/04/21, the company shares recorded $27.28, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/05/21, the same year at $17.51. The company’s shares have inclined by 251.50% in the past year. The 50-day SMA achieved is $23.44 while the 200-day SMA is $18.39. Volume dropped to 2.76 million from 10.86 million in the previous session.
Mersana Therapeutics Inc. [MRSN] Valuation Measures
Notably, Mersana Therapeutics Inc. [MRSN] stock can be helpful for investors to consider historical price-sales ratio, more specifically, a 1382.84 PS value ratio is reported for the last one year of reported earnings. That is higher than the industry average of 20.33.
MRSN Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 17.59 level, and in case of violation of this particular level, it will cause more drop to 16.98 level. On the upper level, 19.88 is still the key resistance. The stock may increase to the subsequent resistance at 19.04. The Relative Strength Index (RSI) pinned on the 14-day chart is 27.83, implying a oversold technical stance while the MACD stands at -4.26, meaning price will decrease in the next trading period. Percent R indicator moved to 94.13%, implying bearish price movement. Stochastic %K at 25.12% suggest holding the stock.
What is the short interest in Mersana Therapeutics Inc.?
Short interest in the Mersana Therapeutics Inc. stock has surged, increasing by 0.24 million shares to total 6.72 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 6.96 million, data from Yahoo Finance shows. The decrease of -3.57% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 12.23% of the overall float for the stock.
Mersana Therapeutics Inc.’s Biggest Shareholders: Who Owns Mersana Therapeutics Inc. [MRSN]?
Filings by Avoro Capital Advisor LLC showed that the firm now holds a total of 6,800,000 shares or roughly 9.93% of the outstanding MRSN shares. This means their shares have increased by 300,000 from the 6,800,000 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, Wellington Management Co. LLP updated stake is worth $96,590,399. Details in the latest 13F filings reveal that Consonance Capital Management LP disposed off their -41.18% stake valued at $88,368,997 while BlackRock Fund Advisors added theirs at $84,539,837. During the last quarter, Consonance Capital Management LP liquidated -2,428,155 of its shares in Mersana Therapeutics Inc. while BlackRock Fund Advisors bought 310,929 shares. The SSgA Funds Management, Inc.’s holdings currently number 2,946,913 shares at $53604347.47. According to the firm’s last 13F report, Sarissa Capital Management LP shares in the company at filing stood at 2,837,000 shares, roughly $72,286,760.
MRSN Earnings Forecast For The Current Quarter
Mersana Therapeutics Inc. [MRSN] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $200k and an earnings per share of -$0.32 for Dec 2020. Looking further ahead, the company is expected to report revenue of $600k at an EPS of -$0.33 for Mar 2021. The estimates represent upside of 111.90% and 0.00% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
MRSN Earnings Estimates For The Current Year
For the financial year, Mersana Therapeutics Inc. [NASDAQ:MRSN] is expected to bring in revenue of $1.01M. The returns are nearly $-41.11 million lower than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.33, lower than that of FY19 by -$0.68. Estimates put this year’s earnings growth at -104.60%, -3.80% for the next. As for sales, forecasts are for a decrease of -97.60% in the current fiscal year and a further 111.90% over the following year.
What are analyst thoughts on Mersana Therapeutics Inc.?
Looking forward to the Mersana Therapeutics Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Mersana Therapeutics Inc. stock at $29.00 within the next 12 months, which represents almost 37.28 per cent growth from its previous closing price of $18.19. The highest analysts’ target for Mersana Therapeutics Inc. stock projections is $33.00 and the lowest one is $23.00. Still, 7 analysts sharing their consensus rating for MRSN stock in 2021 agree that it is a Buy.